Technical Data
T5500-01Q
TIRAP, CT (Toll-interleukin 1 Receptor Domain Containing Adapter Protein, TIR Domain-containing Adapter Protein, Adaptor Protein Wyatt, FLJ42305, MyD88 Adapter-like Protein, MAL)
Description:
Toll-like receptors (TLRs) are signaling molecules that recognize different microbial products during infection and serve as an important link between the innate and adaptive immune responses. These proteins act through adaptor molecules such as TIRAP and MyD88 to activate various kinases and transcription factors. In TIRAP-deficient mice, TLR signaling in response to TLR2 ligands (using either TLR1 and TLR6 as co- receptors) is totally abolished, suggesting that MyD88 and TIRAP work together and both required for TLR2 signaling. Furthermore, these mice are also resistant to the toxic effects of LPS and show defects in NF-kB and MAP kinase activation, suggesting that TIRAP is also involved in TLR4 signaling.

Applications:
Suitable for use in ELISA, Western Blot and Immunohistochemistry. Other applications not tested.

Recommended Dilution:
Western Blot: 0.5-2ug/ml
Immunohistochemistry: 2ug/ml
Optimal dilutions to be determined by the researcher.

Storage and Stability:
May be stored at 4C for short-term only. Aliquot to avoid repeated freezing and thawing. Store at -20C. Aliquots are stable for at least 12 months. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.
TypeIsotypeCloneGrade
PabIgGHighly Purified
SizeStorageShippingSourceHost
50ug-20CBlue IceHumanRabbit
Concentration:
As reported
Immunogen:
Synthetic peptide corresponding to 15aa near the C-terminus of mouse TIRAP.
Purity:
Purified by Ion Exchange chromatography.
Form
Supplied as a liquid in PBS, 0.02% sodium azide.
Specificity:
Recognizes mouse TIRAP. Species Crossreactivity: human and rat.
Intended for research use only. Not for use in human, therapeutic, or diagnostic applications.
1. Vogel, SN. et al. Mol. Interv. 3, 466 (2003). 2. Takeda, K. et al. Annu. Rev. Immunol. 21, 335 (2003). 3. Janeway, CA Jr. et al. Annu. Rev. Immunol. 20, 197 (2002). 4. O'Neill, LAJ. et al. Trends in Imm. 24, 286 (2003). 5. McGettrick, AF. et al. Mol Imm. 41, 577 (2004). 6. Yamamoto, Y. et al. Nature 420, 324 (2002). 7. Hoorng, T. et al. Nature 420, 329 (2002).